Does the GH/IGF-1 axis contribute to skeletal sexual dimorphism? Evidence from mouse studies

Growth Hormone and IGF Research

Volumn 27, Issue , 2016, Pages 7-17

  Liu, Zhongbo ^a   Mohan, Subburaman ^b   Yakar, Shoshana ^a  

^a NEW YORK UNIVERSITY COLLEGE OF DENTISTRY   (United States)

^b Loma Linda VA Healthcare System   (United States)

Author keywords

Bone; Growth hormone receptor (GHR); Insulin like growth factor 1 (IGF 1); Micro computed tomography; Osteocyte; Parathyroid hormone (PTH); Skeletal sexual dimorphism (SSD)

Indexed keywords

ANDROGEN RECEPTOR; ESTROGEN RECEPTOR; GROWTH HORMONE; SEX HORMONE; SOMATOMEDIN C;

AUTOCRINE EFFECT; BONE DEVELOPMENT; BONE GROWTH; BONE STRENGTH; BONE STRUCTURE; HORMONE ACTION; HORMONE BINDING; HORMONE RELEASE; HUMAN; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; RECEPTOR UPREGULATION; REVIEW; SEX DIFFERENCE; ANIMAL; MOUSE; PHYSIOLOGY; SEXUAL DEVELOPMENT; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

ANIMALS; BONE DEVELOPMENT; GROWTH HORMONE; INSULIN-LIKE GROWTH FACTOR I; MICE; MUSCLE, SKELETAL; SEX CHARACTERISTICS; SIGNAL TRANSDUCTION;

EID: 84960323599     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2015.12.004     Document Type: Review

References (83)

1. Tanner J.M., Whitehouse R.H., Marubini E., Resele L.F. The adolescent growth spurt of boys and girls of the Harpenden growth study. Ann. Hum. Biol. 1976, 3:109-126.
2. Veldhuis J.D., Roemmich J.N., Richmond E.J., Rogol A.D., Lovejoy J.C., Sheffield-Moore M., Mauras N., Bowers C.Y. Endocrine control of body composition in infancy, childhood, and puberty. Endocr. Rev. 2005, 26:114-146.
3. Seeman E. Pathogenesis of bone fragility in women and men. Lancet 2002, 359:1841-1850.
4. Seeman E. Clinical review 137: sexual dimorphism in skeletal size, density, and strength. J. Clin. Endocrinol. Metab. 2001, 86:4576-4584.
5. Schoenau E., Neu C.M., Rauch F., Manz F. The development of bone strength at the proximal radius during childhood and adolescence. J. Clin. Endocrinol. Metab. 2001, 86:613-618.
6. Libanati C., Baylink D.J., Lois-Wenzel E., Srinvasan N., Mohan S. Studies on the potential mediators of skeletal changes occurring during puberty in girls. J. Clin. Endocrinol. Metab. 1999, 84:2807-2814.
7. Beck T.J., Looker A.C., Ruff C.B., Sievanen H., Wahner H.W. Structural trends in the aging femoral neck and proximal shaft: analysis of the Third National Health and Nutrition Examination Survey dual-energy X-ray absorptiometry data. J. Bone Miner. Res. 2000, 15:2297-2304.
8. Veldhuis J.D., Anderson S.M., Shah N., Bray M., Vick T., Gentili A., Mulligan T., Johnson M.L., Weltman A., Evans W.S., Iranmanesh A. Neurophysiological regulation and target-tissue impact of the pulsatile mode of growth hormone secretion in the human. Growth Hormon. IGF Res. 2001, 11(Suppl. A):S25-S37.
9. Jansson J.O., Eden S., Isaksson O. Sexual dimorphism in the control of growth hormone secretion. Endocr. Rev. 1985, 6:128-150.
10. MacLeod J.N., Pampori N.A., Shapiro B.H. Sex differences in the ultradian pattern of plasma growth hormone concentrations in mice. J. Endocrinol. 1991, 131:395-399.
11. Clodfelter K.H., Holloway M.G., Hodor P., Park S.H., Ray W.J., Waxman D.J. Sex-dependent liver gene expression is extensive and largely dependent upon signal transducer and activator of transcription 5b (STAT5b): STAT5b-dependent activation of male genes and repression of female genes revealed by microarray analysis. Mol. Endocrinol. 2006, 20:1333-1351.
12. Cohen P., Bright G.M., Rogol A.D., Kappelgaard A.M., Rosenfeld R.G. Effects of dose and gender on the growth and growth factor response to GH in GH-deficient children: implications for efficacy and safety. J. Clin. Endocrinol. Metab. 2002, 87:90-98.
13. Mauras N. Growth hormone and sex steroids. Interactions in puberty. Endocrinol. Metab. Clin. N. Am. 2001, 30:529-544.
14. Span J.P., Pieters G.F., Sweep C.G., Hermus A.R., Smals A.G. Gender difference in insulin-like growth factor I response to growth hormone (GH) treatment in GH-deficient adults: role of sex hormone replacement. J. Clin. Endocrinol. Metab. 2000, 85:1121-1125.
15. Bex M., Abs R., Maiter D., Beckers A., Lamberigts G., Bouillon R. The effects of growth hormone replacement therapy on bone metabolism in adult-onset growth hormone deficiency: a 2-year open randomized controlled multicenter trial. J. Bone Miner. Res. 2002, 17:1081-1094.
16. Gotherstrom G., Svensson J., Koranyi J., Alpsten M., Bosaeus I., Bengtsson B., Johannsson G. A prospective study of 5 years of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass, and metabolic indices. J. Clin. Endocrinol. Metab. 2001, 86:4657-4665.
17. Bengtsson B.A., Abs R., Bennmarker H., Monson J.P., Feldt-Rasmussen U., Hernberg-Stahl E., Westberg B., Wilton P., Wuster C. The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults. KIMS Study Group and the KIMS International Board. J. Clin. Endocrinol. Metab. 1999, 84:3929-3935.
18. Drake W.M., Coyte D., Camacho-Hubner C., Jivanji N.M., Kaltsas G., Wood D.F., Trainer P.J., Grossman A.B., Besser G.M., Monson J.P. Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults. J. Clin. Endocrinol. Metab. 1998, 83:3913-3919.
19. Johannsson G., Rosen T., Bengtsson B.A. Individualized dose titration of growth hormone (GH) during GH replacement in hypopituitary adults. Clin. Endocrinol. 1997, 47:571-581.
20. Johannsson G., Bjarnason R., Bramnert M., Carlsson L.M., Degerblad M., Manhem P., Rosen T., Thoren M., Bengtsson B.A. The individual responsiveness to growth hormone (GH) treatment in GH-deficient adults is dependent on the level of GH-binding protein, body mass index, age, and gender. J. Clin. Endocrinol. Metab. 1996, 81:1575-1581.
21. Kappelgaard A.M., Laursen T. The benefits of growth hormone therapy in patients with Turner syndrome, Noonan syndrome and children born small for gestational age. Growth Hormon. IGF Res. 2011, 21:305-313.
22. Jung H., Land C., Nicolay C., De Schepper J., Blum W.F., Schonau E. Growth response to an individualized versus fixed dose GH treatment in short children born small for gestational age: the OPTIMA study. Eur. J. Endocrinol. 2009, 160:149-156.
23. Callewaert F., Venken K., Kopchick J.J., Torcasio A., van Lenthe G.H., Boonen S., Vanderschueren D. Sexual dimorphism in cortical bone size and strength but not density is determined by independent and time-specific actions of sex steroids and IGF-1: evidence from pubertal mouse models. J. Bone Miner. Res. 2010, 25:617-626.
24. Vandenput L., Boonen S., Van Herck E., Swinnen J.V., Bouillon R., Vanderschueren D. Evidence from the aged orchidectomized male rat model that 17beta-estradiol is a more effective bone-sparing and anabolic agent than 5alpha-dihydrotestosterone. J. Bone Miner. Res. 2002, 17:2080-2086.
25. Govoni K.E., Wergedal J.E., Chadwick R.B., Srivastava A.K., Mohan S. Prepubertal OVX increases IGF-I expression and bone accretion in C57BL/6J mice. Am. J. Physiol. Endocrinol. Metab. 2008, 295:E1172-E1180.
26. Peng Z., Li X., Makela S., Vaananen H.K., Poutanen M. Skeletal changes in transgenic male mice expressing human cytochrome p450 aromatase. J. Bone Miner. Res. 2004, 19:1320-1328.
27. Li X., Nokkala E., Yan W., Streng T., Saarinen N., Warri A., Huhtaniemi I., Santti R., Makela S., Poutanen M. Altered structure and function of reproductive organs in transgenic male mice overexpressing human aromatase. Endocrinology 2001, 142:2435-2442.
28. Sjogren K., Lagerquist M., Moverare-Skrtic S., Andersson N., Windahl S.H., Swanson C., Mohan S., Poutanen M., Ohlsson C. Elevated aromatase expression in osteoblasts leads to increased bone mass without systemic adverse effects. J. Bone Miner. Res. 2009, 24:1263-1270.
29. Lindberg M.K., Alatalo S.L., Halleen J.M., Mohan S., Gustafsson J.A., Ohlsson C. Estrogen receptor specificity in the regulation of the skeleton in female mice. J. Endocrinol. 2001, 171:229-236.
30. Moverare S., Venken K., Eriksson A.L., Andersson N., Skrtic S., Wergedal J., Mohan S., Salmon P., Bouillon R., Gustafsson J.A., Vanderschueren D., Ohlsson C. Differential effects on bone of estrogen receptor alpha and androgen receptor activation in orchidectomized adult male mice. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:13573-13578.
31. Lindberg M.K., Moverare S., Skrtic S., Alatalo S., Halleen J., Mohan S., Gustafsson J.A., Ohlsson C. Two different pathways for the maintenance of trabecular bone in adult male mice. J. Bone Miner. Res. 2002, 17:555-562.
32. Callewaert F., Venken K., Ophoff J., De Gendt K., Torcasio A., van Lenthe G.H., Van Oosterwyck H., Boonen S., Bouillon R., Verhoeven G., Vanderschueren D. Differential regulation of bone and body composition in male mice with combined inactivation of androgen and estrogen receptor-alpha. FASEB J. 2009, 23:232-240.
33. Almeida M., Iyer S., Martin-Millan M., Bartell S.M., Han L., Ambrogini E., Onal M., Xiong J., Weinstein R.S., Jilka R.L., O'Brien C.A., Manolagas S.C. Estrogen receptor-alpha signaling in osteoblast progenitors stimulates cortical bone accrual. J. Clin. Invest. 2013, 123:394-404.
34. Melville K.M., Kelly N.H., Khan S.A., Schimenti J.C., Ross F.P., Main R.P., van der Meulen M.C. Female mice lacking estrogen receptor-alpha in osteoblasts have compromised bone mass and strength. J. Bone Miner. Res. 2014, 29:370-379.
35. Maatta J.A., Buki K.G., Gu G., Alanne M.H., Vaaraniemi J., Liljenback H., Poutanen M., Harkonen P., Vaananen K. Inactivation of estrogen receptor alpha in bone-forming cells induces bone loss in female mice. FASEB J. 2013, 27:478-488.
36. Windahl S.H., Borjesson A.E., Farman H.H., Engdahl C., Moverare-Skrtic S., Sjogren K., Lagerquist M.K., Kindblom J.M., Koskela A., Tuukkanen J., Divieti Pajevic P., Feng J.Q., Dahlman-Wright K., Antonson P., Gustafsson J.A., Ohlsson C. Estrogen receptor-alpha in osteocytes is important for trabecular bone formation in male mice. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:2294-2299.
37. Nakamura T., Imai Y., Matsumoto T., Sato S., Takeuchi K., Igarashi K., Harada Y., Azuma Y., Krust A., Yamamoto Y., Nishina H., Takeda S., Takayanagi H., Metzger D., Kanno J., Takaoka K., Martin T.J., Chambon P., Kato S. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 2007, 130:811-823.
38. Martin-Millan M., Almeida M., Ambrogini E., Han L., Zhao H., Weinstein R.S., Jilka R.L., O'Brien C.A., Manolagas S.C. The estrogen receptor-alpha in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone. Mol. Endocrinol. 2010, 24:323-334.
39. Borjesson A.E., Lagerquist M.K., Liu C., Shao R., Windahl S.H., Karlsson C., Sjogren K., Moverare-Skrtic S., Antal M.C., Krust A., Mohan S., Chambon P., Savendahl L., Ohlsson C. The role of estrogen receptor alpha in growth plate cartilage for longitudinal bone growth. J. Bone Miner. Res. 2010, 25:2690-2700.
40. Ohlsson C., Engdahl C., Borjesson A.E., Windahl S.H., Studer E., Westberg L., Eriksson E., Koskela A., Tuukkanen J., Krust A., Chambon P., Carlsten H., Lagerquist M.K. Estrogen receptor-alpha expression in neuronal cells affects bone mass. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:983-988.
41. Venken K., De Gendt K., Boonen S., Ophoff J., Bouillon R., Swinnen J.V., Verhoeven G., Vanderschueren D. Relative impact of androgen and estrogen receptor activation in the effects of androgens on trabecular and cortical bone in growing male mice: a study in the androgen receptor knockout mouse model. J. Bone Miner. Res. 2006, 21:576-585.
42. Kawano H., Sato T., Yamada T., Matsumoto T., Sekine K., Watanabe T., Nakamura T., Fukuda T., Yoshimura K., Yoshizawa T., Aihara K., Yamamoto Y., Nakamichi Y., Metzger D., Chambon P., Nakamura K., Kawaguchi H., Kato S. Suppressive function of androgen receptor in bone resorption. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:9416-9421.
43. Wiren K.M., Zhang X.W., Toombs A.R., Kasparcova V., Gentile M.A., Harada S., Jepsen K.J. Targeted overexpression of androgen receptor in osteoblasts: unexpected complex bone phenotype in growing animals. Endocrinology 2004, 145:3507-3522.
44. Ucer S., Iyer S., Bartell S.M., Martin-Millan M., Han L., Kim H.N., Weinstein R.S., Jilka R.L., O'Brien C.A., Almeida M., Manolagas S.C. The effects of androgens on murine cortical bone do not require AR or ERalpha signaling in osteoblasts and osteoclasts. J. Bone Miner. Res. 2015, 30:1138-1149.
45. Notini A.J., McManus J.F., Moore A., Bouxsein M., Jimenez M., Chiu W.S., Glatt V., Kream B.E., Handelsman D.J., Morris H.A., Zajac J.D., Davey R.A. Osteoblast deletion of exon 3 of the androgen receptor gene results in trabecular bone loss in adult male mice. J. Bone Miner. Res. 2007, 22:347-356.
46. Maatta J.A., Buki K.G., Ivaska K.K., Nieminen-Pihala V., Elo T.D., Kahkonen T., Poutanen M., Harkonen P., Vaananen K. Inactivation of the androgen receptor in bone-forming cells leads to trabecular bone loss in adult female mice. Bonekey Rep. 2013, 2:440.
47. Sinnesael M., Claessens F., Laurent M., Dubois V., Boonen S., Deboel L., Vanderschueren D. Androgen receptor (AR) in osteocytes is important for the maintenance of male skeletal integrity: evidence from targeted AR disruption in mouse osteocytes. J. Bone Miner. Res. 2012, 27:2535-2543.
48. Linton K., Howarth C., Wappett M., Newton G., Lachel C., Iqbal J., Pepper S., Byers R., Chan W.J., Radford J. Microarray gene expression analysis of fixed archival tissue permits molecular classification and identification of potential therapeutic targets in diffuse large B-cell lymphoma. J. Mol. Diagn. 2012, 14:223-232.
49. Windahl S.H., Vidal O., Andersson G., Gustafsson J.A., Ohlsson C. Increased cortical bone mineral content but unchanged trabecular bone mineral density in female ERbeta(-/-) mice. J. Clin. Invest. 1999, 104:895-901.
50. Flores-Morales A., Stahlberg N., Tollet-Egnell P., Lundeberg J., Malek R.L., Quackenbush J., Lee N.H., Norstedt G. Microarray analysis of the in vivo effects of hypophysectomy and growth hormone treatment on gene expression in the rat. Endocrinology 2001, 142:3163-3176.
51. Veldhuis J.D., Roemmich J.N., Rogol A.D. Gender and sexual maturation-dependent contrasts in the neuroregulation of growth hormone secretion in prepubertal and late adolescent males and females-a general clinical research center-based study. J. Clin. Endocrinol. Metab. 2000, 85:2385-2394.
52. Kerrigan J.R., Rogol A.D. The impact of gonadal steroid hormone action on growth hormone secretion during childhood and adolescence. Endocr. Rev. 1992, 13:281-298.
53. Mauras N., Blizzard R.M., Link K., Johnson M.L., Rogol A.D., Veldhuis J.D. Augmentation of growth hormone secretion during puberty: evidence for a pulse amplitude-modulated phenomenon. J. Clin. Endocrinol. Metab. 1987, 64:596-601.
54. Veldhuis J.D., Metzger D.L., Martha P.M., Mauras N., Kerrigan J.R., Keenan B., Rogol A.D., Pincus S.M. Estrogen and testosterone, but not a nonaromatizable androgen, direct network integration of the hypothalamo-somatotrope (growth hormone)-insulin-like growth factor I axis in the human: evidence from pubertal pathophysiology and sex-steroid hormone replacement. J. Clin. Endocrinol. Metab. 1997, 82:3414-3420.
55. Eakman G.D., Dallas J.S., Ponder S.W., Keenan B.S. The effects of testosterone and dihydrotestosterone on hypothalamic regulation of growth hormone secretion. J. Clin. Endocrinol. Metab. 1996, 81:1217-1223.
56. Keenan B.S., Richards G.E., Ponder S.W., Dallas J.S., Nagamani M., Smith E.R. Androgen-stimulated pubertal growth: the effects of testosterone and dihydrotestosterone on growth hormone and insulin-like growth factor-I in the treatment of short stature and delayed puberty. J. Clin. Endocrinol. Metab. 1993, 76:996-1001.
57. Martha P.M., Rogol A.D., Veldhuis J.D., Kerrigan J.R., Goodman D.W., Blizzard R.M. Alterations in the pulsatile properties of circulating growth hormone concentrations during puberty in boys. J. Clin. Endocrinol. Metab. 1989, 69:563-570.
58. Mauras N., Rogol A.D., Veldhuis J.D. Specific, time-dependent actions of low-dose ethinyl estradiol administration on the episodic release of growth hormone, follicle-stimulating hormone, and luteinizing hormone in prepubertal girls with Turner's syndrome. J. Clin. Endocrinol. Metab. 1989, 69:1053-1058.
59. Mericq M.V., Eggers M., Avila A., Cutler G.B., Cassorla F. Near final height in pubertal growth hormone (GH)-deficient patients treated with GH alone or in combination with luteinizing hormone-releasing hormone analog: results of a prospective, randomized trial. J. Clin. Endocrinol. Metab. 2000, 85:569-573.
60. Neely E.K., Bachrach L.K., Hintz R.L., Habiby R.L., Slemenda C.W., Feezle L., Pescovitz O.H. Bone mineral density during treatment of central precocious puberty. J. Pediatr. 1995, 127:819-822.
61. Attie K.M., Ramirez N.R., Conte F.A., Kaplan S.L., Grumbach M.M. The pubertal growth spurt in eight patients with true precocious puberty and growth hormone deficiency: evidence for a direct role of sex steroids. J. Clin. Endocrinol. Metab. 1990, 71:975-983.
62. Venken K., Schuit F., Van Lommel L., Tsukamoto K., Kopchick J.J., Coschigano K., Ohlsson C., Moverare S., Boonen S., Bouillon R., Vanderschueren D. Growth without growth hormone receptor: estradiol is a major growth hormone-independent regulator of hepatic IGF-I synthesis. J. Bone Miner. Res. 2005, 20:2138-2149.
63. Bikle D., Majumdar S., Laib A., Powell-Braxton L., Rosen C., Beamer W., Nauman E., Leary C., Halloran B. The skeletal structure of insulin-like growth factor I-deficient mice. J. Bone Miner. Res. 2001, 16:2320-2329.
64. Chandrashekar V., Dawson C.R., Martin E.R., Rocha J.S., Bartke A., Kopchick J.J. Age-related alterations in pituitary and testicular functions in long-lived growth hormone receptor gene-disrupted mice. Endocrinology 2007, 148:6019-6025.
65. Liu J.L., Yakar S., LeRoith D. Mice deficient in liver production of insulin-like growth factor I display sexual dimorphism in growth hormone-stimulated postnatal growth. Endocrinology 2000, 141:4436-4441.
66. Yakar S., Canalis E., Sun H., Mejia W., Kawashima Y., Nasser P., Courtland H.W., Williams V., Bouxsein M., Rosen C., Jepsen K.J. Serum IGF-1 determines skeletal strength by regulating subperiosteal expansion and trait interactions. J. Bone Miner. Res. 2009, 24:1481-1492.
67. Fritton J.C., Emerton K.B., Sun H., Kawashima Y., Mejia W., Wu Y., Rosen C.J., Panus D., Bouxsein M., Majeska R.J., Schaffler M.B., Yakar S. Growth hormone protects against ovariectomy-induced bone loss in states of low circulating insulin-like growth factor (IGF-1). J. Bone Miner. Res. 2010, 25:235-246.
68. Elis S., Courtland H.W., Wu Y., Fritton J.C., Sun H., Rosen C.J., Yakar S. Elevated serum IGF-1 levels synergize PTH action on the skeleton only when the tissue IGF-1 axis is intact. J. Bone Miner. Res. 2010, 25:2051-2058.
69. Elis S., Courtland H.W., Wu Y., Rosen C.J., Sun H., Jepsen K.J., Majeska R.J., Yakar S. Elevated serum levels of IGF-1 are sufficient to establish normal body size and skeletal properties even in the absence of tissue IGF-1. J. Bone Miner. Res. 2010, 25:1257-1266.
70. Elis S., Wu Y., Courtland H.W., Sun H., Rosen C.J., Adamo M.L., Yakar S. Increased serum IGF-1 levels protect the musculoskeletal system but are associated with elevated oxidative stress markers and increased mortality independent of tissue igf1 gene expression. Aging Cell 2011, 10:547-550.
71. Wu Y., Sun H., Basta-Pljakic J., Cardoso L., Kennedy O.D., Jasper H., Domene H., Karabatas L., Guida C., Schaffler M.B., Rosen C.J., Yakar S. Serum IGF-1 is insufficient to restore skeletal size in the total absence of the growth hormone receptor. J. Bone Miner. Res. 2013, 28:1575-1586.
72. DeMambro V.E., Clemmons D.R., Horton L.G., Bouxsein M.L., Wood T.L., Beamer W.G., Canalis E., Rosen C.J. Gender-specific changes in bone turnover and skeletal architecture in igfbp-2-null mice. Endocrinology 2008, 149:2051-2061.
73. Ning Y., Schuller A.G., Bradshaw S., Rotwein P., Ludwig T., Frystyk J., Pintar J.E. Diminished growth and enhanced glucose metabolism in triple knockout mice containing mutations of insulin-like growth factor binding protein-3, -4, and -5. Mol. Endocrinol. 2006, 20:2173-2186.
74. Zhang M., Faugere M.C., Malluche H., Rosen C.J., Chernausek S.D., Clemens T.L. Paracrine overexpression of IGFBP-4 in osteoblasts of transgenic mice decreases bone turnover and causes global growth retardation. J. Bone Miner. Res. 2003, 18:836-843.
75. Salih D.A., Mohan S., Kasukawa Y., Tripathi G., Lovett F.A., Anderson N.F., Carter E.J., Wergedal J.E., Baylink D.J., Pell J.M. Insulin-like growth factor-binding protein-5 induces a gender-related decrease in bone mineral density in transgenic mice. Endocrinology 2005, 146:931-940.
76. Kesavan C., Wergedal J.E., Lau K.H., Mohan S. Conditional disruption of IGF-I gene in type 1alpha collagen-expressing cells shows an essential role of IGF-I in skeletal anabolic response to loading. Am. J. Physiol. Endocrinol. Metab. 2011, 301:E1191-E1197.
77. Govoni K.E., Wergedal J.E., Florin L., Angel P., Baylink D.J., Mohan S. Conditional deletion of insulin-like growth factor-I in collagen type 1alpha2-expressing cells results in postnatal lethality and a dramatic reduction in bone accretion. Endocrinology 2007, 148:5706-5715.
78. Zhang M., Xuan S., Bouxsein M.L., von Stechow D., Akeno N., Faugere M.C., Malluche H., Zhao G., Rosen C.J., Efstratiadis A., Clemens T.L. Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J. Biol. Chem. 2002, 277:44005-44012.
79. Wu S., Yang W., De Luca F. Insulin-like growth factor-independent effects of growth hormone on growth plate chondrogenesis and longitudinal bone growth. Endocrinology 2015, 156:2541-2551.
80. Wang Y., Cheng Z., Elalieh H.Z., Nakamura E., Nguyen M.T., Mackem S., Clemens T.L., Bikle D.D., Chang W. IGF-1R signaling in chondrocytes modulates growth plate development by interacting with the PTHrP/Ihh pathway. J. Bone Miner. Res. 2011, 26:1437-1446.
81. Govoni K.E., Lee S.K., Chung Y.S., Behringer R.R., Wergedal J.E., Baylink D.J., Mohan S. Disruption of insulin-like growth factor-I expression in type IIalphaI collagen-expressing cells reduces bone length and width in mice. Physiol. Genomics 2007, 30:354-362.
82. Sheng M.H., Zhou X.D., Bonewald L.F., Baylink D.J., Lau K.H. Disruption of the insulin-like growth factor-1 gene in osteocytes impairs developmental bone growth in mice. Bone 2013, 52:133-144.
83. Liu Z., Kennedy O.D., Cardoso L., Basta-Pljakic J., Partridge N.C., Schaffler M.B., Rosen C.J., Yakar S. DMP-1-mediated Ghr gene recombination compromises skeletal development and impairs skeletal response to intermittent PTH. FASEB J. 2015.